Phreesia (PHR) Insider Lainie Goldstein Buys $185K of Stock

Lainie Goldstein purchased 19,290 shares of Phreesia, Inc. (NYSE: PHR) at a price of $9.59 each on June 24, 2026. This trade was valued at approximately $185,000. The purchase reflects continued insider activity in the company as it navigates the healthcare technology sector.

Inside Lainie Goldstein's Trade

Goldstein's acquisition aligns with other recent insider purchases on the same day, including Jon Kessler, Gillian Munson, Lisa Egbuonu-Davis, and Ramin Sayar, all buying 19,290 shares at the same price. This coordinated buying could signify collective confidence among insiders in Phreesia's future performance. The stock was trading at $9.13 as of publication, indicating it is currently below its 50-day moving average of $11.15.

Other Institutional Activity in Phreesia

Several other institutional players reported their positions in Phreesia around the same time. Pale Fire Capital SE increased its holdings by 275,047 shares, ending with 8,924,329 shares valued at about $97.5 million. Blackrock Inc. added 1,099,420 shares for a total of 7,019,832 shares worth approximately $76.7 million. AQR Capital Management, LLC boosted its stake by 1,298,856 shares, bringing its total to 3,151,453 shares valued at about $34.4 million. Conversely, Vanguard Portfolio Management LLC reduced its position by 347,183 shares, now holding 2,987,907 shares worth approximately $32.7 million.

Phreesia, Inc. Stock Down 9.1%

On Saturday, the shares of Phreesia were priced at $9.13, down from the previous close of $10.04. This price is well below the 52-week high of $25.00 and close to its low of $7.77. The stock has been facing challenges but is currently trading below its 200-day average.

Recent Earnings

Phreesia reported revenue of approximately $507.8 million, which reflects a growth rate of 10.4%. The company’s earnings per share (EPS) is $0.18, with a net margin of about 2.06%. The next earnings date is scheduled for December 7, 2026.

Insider Buying and Selling at Phreesia, Inc.

On June 24, 2026, several insiders made significant purchases: Jon Kessler, Gillian Munson, Lisa Egbuonu-Davis, and Ramin Sayar each bought 19,290 shares at an average price of $9.59, totaling around $185,000 for each insider. These transactions were not planned, indicating possibly opportunistic buying.

Analysts Set New Price Targets

Analysts have recently provided updates on Phreesia. On October 12, 2026, Barclays maintained an Equal-Weight rating with a price target of $11.00, up from $10.00. On September 8, 2026, Raymond James downgraded the stock to Market Perform. DA Davidson and Freedom Capital Markets both maintained Buy ratings with targets of $13.00 and $14.00, respectively.

About Phreesia, Inc.

Phreesia, Inc. is a healthcare technology company that offers a software platform designed to streamline patient engagement and payment processes in the U.S. and Canada. Its recent insider activity may suggest that executives are optimistic about the company's direction and performance as it continues to grow in the competitive healthcare sector.

Bottom Line

Investors should keep an eye on Phreesia's upcoming earnings report on December 7, 2026. The recent insider buying indicates a potential confidence in the company's strategy. Remember, this insider trading data reflects past transactions and may not represent the current holdings of those insiders.